^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Cancer

    Related cancers:
    1d
    FLAGSHP-1: A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=90, Active, not recruiting, Erasca, Inc. | N=200 --> 90 | Trial completion date: Feb 2026 --> Jun 2026 | Trial primary completion date: Nov 2025 --> Feb 2026
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • ERAS-601
    1d
    KN035-CN-017: Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC (clinicaltrials.gov)
    P3, N=390, Recruiting, 3D Medicines (Sichuan) Co., Ltd. | Trial completion date: Sep 2027 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Enweida (envafolimab)
    1d
    NIBIT-ML-1: A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1 (2024-518891-29-00)
    P1/2, N=148, Recruiting, Fondazione NIBIT Onlus | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • BRAF mutation • ALK translocation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Inqovi (decitabine/cedazuridine)
    1d
    SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, AbbVie | N=27 --> 50
    Enrollment change • Adverse events
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • Zepzelca (lurbinectedin) • ABBV-706
    1d
    C6461001: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (2025-523461-17-01)
    P2/3, N=203, Not yet recruiting, Pfizer Inc.
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed
    1d
    A clinical study of V940 in people with non-small cell lung cancer (V940-013) (2025-520902-37-00)
    P1/2, N=15, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    1d
    HLX43-NSCLC201: Testing HLX43 in Advanced Lung Cancer (Non-Small Cell): A Global Safety and Effectiveness Study (2025-523803-31-00)
    P1/2, N=22, Not yet recruiting, Shanghai Henlius Biotech Inc.
    New P1/2 trial
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    PD-L1 expression • EGFR mutation • MET exon 14 mutation
    |
    HLX43
    1d
    A Mobile Patient Health Technology Intervention for Improving Lung Cancer Screening Rates in Eligible High Risk Patients (clinicaltrials.gov)
    P=N/A, N=27000, Recruiting, Wake Forest University Health Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Recruiting, 3D Medicines (Sichuan) Co., Ltd. | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    sunitinib • Lenvima (lenvatinib) • Enweida (envafolimab)
    1d
    The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients (clinicaltrials.gov)
    P2, N=35, Recruiting, The Third Xiangya Hospital of Central South University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    cisplatin • carboplatin • paclitaxel • Tyvyt (sintilimab)
    1d
    Onkoras-101: Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=350, Recruiting, TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | N=250 --> 350 | Trial completion date: Feb 2028 --> Sep 2031 | Trial primary completion date: Aug 2027 --> Apr 2031
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab)
    1d
    K-NADIR: Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (clinicaltrials.gov)
    P2, N=30, Recruiting, Jianxing He
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    carboplatin • Tyvyt (sintilimab) • albumin-bound paclitaxel • Dupert (fulzerasib)